AstraZeneca Plc has enrolled the first patient in a Phase 3 development programme for olaparib in patients with ovarian cancer. Olaparib was discontinued in this indication in 2011 but is now being re-started in patients with BRCA-mutated disease. ---Subscribe to MedNous to access this article--- Clinical Research Company News
